This study, using data from the EuroTR registry, investigated the impact of prior heart failure hospitalizations (HFHs) on outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair (T-TEER) for symptomatic tricuspid regurgitation (TR). Among 1000 patients analyzed, 63.9% experienced at least one HFH in the year before T-TEER. These patients presented with more advanced heart failure symptoms, worse renal function, and higher natriuretic peptide levels. Despite similar procedural success across all groups—defined as achieving residual TR grade ≤2—the presence of prior HFHs was linked to significantly higher risks of all-cause mortality and combined mortality/HFH outcomes.
This study, published in the European Journal of Heart Failure, explores the clinical characteristics, management, and outcomes of patients with heart failure (HF) who also have a history of cancer. Drawing from the ESC-HFA EORP Heart Failure Long-Term Registry, the research evaluated 9,017 patients, 904 (10%) of whom had a past cancer diagnosis. The most common cancers reported were breast, prostate, and gastrointestinal.
This study, led by Carbonneau et al., investigates the connection between cardiovascular health (CVH) and DNA methylation (DNAm), focusing on the American Heart Association’s Life’s Essential 8 (LE8) metric. LE8 incorporates four health behaviors (diet, physical activity, smoking, sleep) and four health factors (BMI, blood pressure, blood glucose, cholesterol) to quantify overall CVH. Despite its recognized value, over 80% of U.S. adults have poor or moderate LE8 scores.
A new consensus statement from the American Diabetes Association (ADA), published in Diabetes Care (July 2025), outlines a clear and practical strategy for identifying and risk-stratifying patients with metabolic dysfunction–associated liver disease (MASLD). MASLD is becoming a leading cause of cirrhosis and liver failure, yet it remains underdiagnosed due to the complexity of available diagnostic tools. The ADA emphasizes the Fibrosis-4 (FIB-4) index as the best initial test for evaluating liver fibrosis in patients with prediabetes or type 2 diabetes, especially those with obesity.
The U.S. FDA has approved KERENDIA® (finerenone), a non-steroidal mineralocorticoid receptor antagonist (nsMRA), for treating adults with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥40%. This approval follows a Priority Review and is based on findings from the Phase III FINEARTS-HF trial. The new indication allows KERENDIA to be used for reducing cardiovascular (CV) death, hospitalization for heart failure, and urgent heart failure visits in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).
